TABLE 3.
Preclinical Use of TNFR2 agonists and antagonists.
| Molecule | Disease model | References |
| TNFR2 agonists | ||
| STAR2 | Graft versus host disese (GvHD) | Chopra et al., 2016 |
| STAR2, EHD2-sc-mTNFR2 | Collagen-induced arthritis | Fischer et al., 2018; Lamontain et al., 2019 |
| EHD2-scTNFR2 | NMDA-induced neurodegeneration model of Alzheimer’s disease | Dong et al., 2016 |
| EHD2-sc-mTNFR2 | Spinal cord injury (SCI) | Gerald et al., 2019 |
| EHD2-sc-mTNFR2 | Chronic constriction injury (CCI) model of neuropathic pain | Fischer et al., 2019b |
| EHD2-sc-mTNFR2 | Experimental autoimmune encephalomyelitis (EAE) | Fischer et al., 2019a |
| Y9 (agonistic anti-TNFR2 antibody) | Syngeneic mouse tumor models | Tam et al., 2019 |
| TNFR2 antagonists | ||
| TNFR2 antagonistic antibodies | Ovarian cancer (patient material) | Torrey et al., 2017 |
| TNFR2 antagonistic antibodies | Sézary syndrome (patient material) | Torrey et al., 2019 |